New Weight Loss Drug Mazdutide Shows 14% Weight Reduction in Chinese Adults
Phase 3 trial shows once-weekly mazdutide injections led to significant weight loss with minimal side effects in overweight Chinese adults.
Summary
A major phase 3 trial in China tested mazdutide, a new dual-action weight loss drug that targets both GLP-1 and glucagon receptors. Over 600 overweight adults received weekly injections for 48 weeks. Results were impressive: participants lost an average of 11-14% of their body weight, compared to no weight loss with placebo. Nearly half of those on the higher dose lost at least 15% of their weight. The drug also improved cardiovascular and metabolic markers. Side effects were mostly mild gastrointestinal issues, with very low discontinuation rates.
Detailed Summary
This groundbreaking study represents a significant advance in obesity treatment, testing mazdutide—a novel dual-action drug that simultaneously targets GLP-1 and glucagon receptors. Unlike existing single-target medications, this approach may offer superior weight loss results.
Researchers conducted a rigorous 48-week phase 3 trial across multiple Chinese medical centers, enrolling 610 adults with BMI ≥28 or BMI 24-28 with weight-related health conditions. Participants received weekly injections of either 4mg mazdutide, 6mg mazdutide, or placebo.
The results were remarkable. At 32 weeks, participants lost 10% (4mg dose) and 12.6% (6mg dose) of their body weight versus minimal change with placebo. By 48 weeks, weight loss reached 11% and 14% respectively. Crucially, 82% of high-dose participants achieved clinically meaningful 5% weight loss, while nearly half lost 15% or more—levels typically seen only with bariatric surgery.
Beyond weight loss, mazdutide improved all measured cardiovascular and metabolic parameters, suggesting comprehensive health benefits. The safety profile was encouraging, with mostly mild-to-moderate gastrointestinal side effects and discontinuation rates under 2%.
These findings position mazdutide as a potentially game-changing obesity treatment, offering weight loss comparable to surgical interventions through a weekly injection. However, the study was limited to Chinese populations, and long-term safety data beyond 48 weeks remains unknown.
Key Findings
- Weekly mazdutide injections produced 11-14% weight loss over 48 weeks
- 82% of participants achieved clinically meaningful 5% weight reduction
- Nearly half lost 15% or more body weight on higher dose
- Improved cardiovascular and metabolic markers across all measures
- Low discontinuation rate under 2% due to mild side effects
Methodology
Phase 3 double-blind, placebo-controlled trial with 610 Chinese adults randomized 1:1:1 to receive 4mg mazdutide, 6mg mazdutide, or placebo weekly for 48 weeks. Primary endpoints measured at week 32 using treatment-policy estimand analysis.
Study Limitations
Summary based on abstract only. Study limited to Chinese population, requiring validation in other ethnic groups. Long-term safety and efficacy beyond 48 weeks unknown. Cost and accessibility factors not addressed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.